Trials / Completed
CompletedNCT03423810
Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- University of Kansas Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like protein) in the urine that is changed after treatment of hydralazine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydralazine | Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day. |
Timeline
- Start date
- 2018-04-23
- Primary completion
- 2020-01-30
- Completion
- 2020-01-30
- First posted
- 2018-02-06
- Last updated
- 2020-02-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03423810. Inclusion in this directory is not an endorsement.